Biomax Joins Austrian Personalized Medicine Consortium

Apr 25, 2008

NEW YORK (GenomeWeb News) - Biomax Informatics said this week that it has been selected as a consortium partner in Austria’s OncoTyrol project Center for Personalized Cancer Medicine.

The four-year, €28 million ($43.7 million) OncoTyrol initiative focuses on “translating genomic, proteomic and metabolomic research into innovative, individualized, and cost-effective approaches for cancer diagnosis and treatment,” Biomax said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Pushed Aside

The New York Times Magazine examines gender discrimination at the Salk Institute.

Dismissals at MD Anderson

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

Looking Into It

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

This Week in PLOS

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.

Menu